AQEMIA Secures $100 Million in Funding for Global Expansion

Deal News | Dec 10, 2024 | Cathay Capital

AQEMIA Secures $100 Million in Funding for Global Expansion

AQEMIA, a pioneering techbio company, has reached a cumulative funding milestone of $100 million following a recent $38 million funding round led by Cathay Innovation. This achievement comes after demonstrating impressive results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The funds will support AQEMIA's development goals, including preparations for clinical trials. AQEMIA plans to expand globally, starting with a new London office scheduled to open in January 2025, leveraging the UK's life sciences and techbio talent pool. Cathay Innovation's partnership extends beyond capital, offering expertise in scaling AI-driven companies worldwide. AQEMIA's innovative approach combines AI with quantum mechanics to enhance drug discovery processes, moving towards clinical trials and building successful collaborations, notably including a $140 million partnership with Sanofi.

Sectors

  • Biotechnology
  • Venture Capital

Geography

  • United Kingdom – AQEMIA is set to open a new office in London, emphasizing expansion and recruitment in the UK.
  • France – AQEMIA is based in Paris, marking France as a key geographical location in the company's operations and strategic planning.

Industry

  • Biotechnology – The article focuses on AQEMIA, a techbio company involved in drug discovery using innovative AI and quantum mechanics, placing it within the biotechnology sector.
  • Venture Capital – Cathay Innovation, a venture capital firm, is actively involved in the funding round, highlighting the venture capital industry's role in financing growth-stage companies.

Financials

  • $100 million – The total cumulative funding raised by AQEMIA.
  • $38 million – The most recent funding round led by Cathay Innovation.
  • $140 million – The value of the collaboration between AQEMIA and Sanofi.

Participants

NameRoleTypeDescription
AQEMIATarget CompanyCompanyA techbio company specializing in AI-driven drug discovery, reaching significant funding milestones to expand globally.
Cathay InnovationLead InvestorCompanyA multistage venture capital firm leading the recent $38 million funding round for AQEMIA.
Maximilien LevesqueCEO and Co-founderPersonCEO and co-founder of AQEMIA, driving the company's vision and global expansion efforts.
Jacky AbitbolPartner at Cathay InnovationPersonProvides strategic partnership and support from Cathay Innovation to AQEMIA.
SanofiCollaborative PartnerCompanyA pharmaceutical company that engaged in a $140 million collaboration with AQEMIA, underscoring the techbio's potent drug discovery platform.
WendelInvestorCompanyOne of the historical investors in AQEMIA.
Bpifrance Large VentureInvestorCompanyAnother historical investor in AQEMIA.
EurazeoInvestorCompanyA historical investor participating in AQEMIA's funding.
ElaiaInvestorCompanyA historical investor in AQEMIA.